Now showing items 21-30 of 33
Encouraging innovative treatment of neglected diseases through priority review vouchers
(Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, 2009-09-01)
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
(Cancer Prev Res (Phila), 2008-07)
Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face significant scientific, regulatory, and economic barriers, however, ...
Do faster food and drug administration drug reviews adversely affect patient safety? An analysis of the 1992 prescription drug user fee act
(Journal of Law and Economics, 2008-05-01)
Food and Drug Administration (FDA) review times have significantly declined under the user-fee regime. This situation has provoked concerns that drug safety has been adversely affected. Combining information from several ...
Returns on R&D for 1990s New Drug Introductions
Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure
(Consolidation and Competition in the Pharmaceutical Industry, 2001)
Patents, Innovation and Access to New Pharmaceuticals
(Journal of International Economic Law, 2002-02)
Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)
Spending on postapproval drug safety.
(Health Aff (Millwood), 2006-03)
Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...
Competition between Generic and Branded Drugs
(Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective, 2007-04-30)
The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being ...
Follow-on biologics: data exclusivity and the balance between innovation and competition
(Nature Reviews Drug Discovery, 2008-06)